3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
2
Status
Recruiting
2
Completed
2
Active not recruiting
2
Withdrawn
1
Unknown
1
Terminated
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Lung Neoplasms
1
Liver Diseases
1
Carcinoma, Hepatocellular
1
Interventions
pembrolizumab
219
Carboplatin
218
Specimen Handling
198
Cisplatin
188
Magnetic Resonance Spectroscopy
168
Radiotherapy
152
Bevacizumab
142
Gemcitabine
135
Cyclophosphamide
133
Drug Therapy
118
Capecitabine
118
Paclitaxel
112
Oxaliplatin
110
Biopsy
107
venetoclax
102
Nivolumab
101
Rituximab
83
tislelizumab
81
durvalumab
81
toripalimab
77
Fluorouracil
73
Etoposide
72
Dexamethasone
70
sintilimab
67
Radiosurgery
67
Docetaxel
67
Pemetrexed
65
atezolizumab
64
Azacitidine
63
Injections
62
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Recruiting
×
Adjuvants, Pharmaceutic
×
Clear all
NCT06788912
2026-06-01
MK-3475-01E
Merck Sharp & Dohme LLC
Phase 2
Recruiting
60 enrolled
NCT04727307
2025-09-30
AB-LATE02
University Hospital, Montpellier
Phase 2
Recruiting
202 enrolled